Events

Pharmaceutical Life Cycle Management: Updates on Navigating the IP, FDA and Antitrust Terrain

Events / Wednesday, April 5, 2017
Noon to 2 p.m. EDT

There’s been a sea change in the political climate. The regulatory forecast is still uncertain, and pharmaceutical evolution continues to develop.

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced considerable complexity and risk into these strategies.

Be prepared for what the next year may bring by attending this important webinar, which brings together our experienced professionals to talk about these issues and approaches for successful pharmaceutical life cycle management.

Presenters:
  • Carl W. Hittinger, Partner, Philadelphia
  • Lee H. Rosebush, Partner, Washington, D.C.
  • Lance L. Shea, Partner, Washington, D.C.
  • S. Maurice Valla, Partner, Philadelphia

2.0 hours of CLE credit offered in MD, VA, NY, and NJ. Additional states may be available upon request.

For questions, please contact Natalia Egan at 216.430.2941.

Register now >>

Webinar Details

DATE
  • Wednesday, April 5, 2017
TIME
  • Noon to 2 p.m. EDT

Blog

In The Blogs

Previous Next
Antitrust Advocate
The Trump DOJ’s View on Merger Enforcement and Remedies Explained
November 20, 2017
President Trump’s head of the Department of Justice’s Antitrust Division, Makan Delrahim, recently explained that the division will cut back on behavioral commitments such as consent orders regulating conduct and will instead rely more on...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
November 13, 2017
SENATE COMMITTEES TO REVIEW TRUMP’S HHS PICK The year-end schedules of the Senate HELP and Finance committees just became more clogged, as the two panels will lead the review of President Trump’s nominee to be Health & Human Services (HHS)...
Read More ->
Antitrust Advocate
Supreme Court to Decide First Antitrust Case in Two Years
November 9, 2017
On Oct. 16, the U.S. Supreme Court granted certiorari in United States v. American Express, the court’s first antitrust case of the 2017 term and the first antitrust case they have reviewed since 2015. The American Express case presents...
Read More ->
IP Intelligence: Insight on Intellectual Property
Federal Circuit Splits on Approach to Analyzing Graham Factors
November 6, 2017
In Merck Sharp & Dohme Corp. v. Hospira, Inc.,[1] the Federal Circuit affirmed the lower court’s ruling that the asserted claims of Merck’s U.S. Patent No. 6,486,150 (the ’150 patent) were obvious despite evidence of commercial success and...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
November 6, 2017
December Most Likely Timetable for CHIP Even After House Approval The House last week voted to renew the Children’s Health Insurance Program (CHIP) through 2022, but disagreements over how to pay for the program are likely to delay...
Read More ->